These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29357903)

  • 1. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
    Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
    Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials.
    Furlong P; Dugar A; White M
    Res Involv Engagem; 2024 Jan; 10(1):1. PubMed ID: 38167117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Advocacy groups are the connectors': Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics.
    Nguyen CQ; Kariyawasam D; Alba-Concepcion K; Grattan S; Hetherington K; Wakefield CE; Woolfenden S; Dale RC; Palmer EE; Farrar MA
    Health Expect; 2022 Dec; 25(6):3175-3191. PubMed ID: 36307981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations.
    Dombernowsky T; Haedersdal M; Lassen U; Thomsen SF
    Trials; 2019 Dec; 20(1):708. PubMed ID: 31829234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
    Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
    Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from an Experiential Approach to Patient Community Engagement in Rare Disease.
    Smith J; Damm K; Hover G; Chien J
    Clin Ther; 2021 Feb; 43(2):421-429. PubMed ID: 33375998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop.
    Mikami K; Sturdy S
    Res Involv Engagem; 2017; 3():14. PubMed ID: 29062539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIH consensus development conference draft statement on vaginal birth after cesarean: new insights.
    Cunningham FG; Bangdiwala SI; Brown SS; Dean TM; Frederiksen M; Rowland Hogue CJ; King T; Spencer Lukacz E; McCullough LB; Nicholson W; Petit NF; Probstfield JL; Viguera AC; Wong CA; Zimmet SC
    NIH Consens State Sci Statements; 2010 Mar; 27(3):1-42. PubMed ID: 20228855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark.
    Mulinari S; Pashley D; Ozieranski P
    Health Policy; 2022 Dec; 126(12):1256-1262. PubMed ID: 36371347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building cross-border collaborations to increase diversity and accelerate rare disease drug development - meeting report from the inaugural IndoUSrare Annual Conference 2021.
    Khera HK; Venugopal N; Karur RT; Mishra R; Kartha RV; Rajasimha HK
    Ther Adv Rare Dis; 2022; 3():26330040221133124. PubMed ID: 37180411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Biopharmaceutical Company Experience with Patient-centric Initiatives.
    Michaels DL; Lamberti MJ; Peña Y; Kunz BL; Getz K
    Clin Ther; 2019 Aug; 41(8):1427-1438. PubMed ID: 31443914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.
    Wolka AM; Fairchild AO; Reed SD; Anglin G; Johnson FR; Siegel M; Noel R
    Ther Innov Regul Sci; 2018 Jul; 52(4):507-513. PubMed ID: 29714550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMCP Partnership Forum: Preparing for and managing rare diseases.
    J Manag Care Spec Pharm; 2021 Mar; 27(3):415-420. PubMed ID: 33538235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.